RecruitingNCT04798690

Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

Open, Multi-center, Non-interventional, Prospective/ Retrospective Observational Study on Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature


Sponsor

Dong-A ST Co., Ltd.

Enrollment

2,500 participants

Start Date

Feb 8, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.


Eligibility

Min Age: 2 Years

Inclusion Criteria2

  • Children with short stature by growth hormone deficiency(GHD) or idiopathic short stature (ISS) or turner's syndrome(TS) or small for gestational age(SGA)
  • Children who has official height record at least 6 months prior

Exclusion Criteria1

  • Children with Epiphyseal closure

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Yonsei University Health System, Severance Hospital

Seoul, Seodaemun-gu, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04798690


Related Trials